<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02726789</url>
  </required_header>
  <id_info>
    <org_study_id>REP 201</org_study_id>
    <nct_id>NCT02726789</nct_id>
  </id_info>
  <brief_title>Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B</brief_title>
  <official_title>Therapeutic Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Replicor Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Replicor Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The REP 201 protocol is a small exploratory study assessing the antiviral effects and
      tolerability of REP 2139-Ca when used with a full course of pegylated interferon (48 weeks)
      in treatment naive patients or in patients already receiving entecavir and continuing
      entecavir with treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis B is a long term condition caused by infection of the body with the
      hepatitis B virus (HBV). This infection often results in inflammation or scarring of the
      liver and can eventually lead to liver cirrhosis and liver failure. These infections are also
      one of the major causes of the development of hepatocellular carcinoma (liver cancer).

      Although some drugs have been approved to treat chronic hepatitis B infections, they do not
      provide a complete cure except in rare cases (a cure generally means that a person loses the
      hepatitis B virus from the blood and the liver and develops a durable immunological control
      of subsequent HBV infection). However, these drugs do significantly decrease the risk of
      liver damage and liver cancer arising from the presence of a chronic liver infection by
      slowing or stopping the production of infectious virus. Thus the primary problem associated
      with currently available drugs is the lack of clearance of the virus from the hepatocytes
      which necessitates long term treatment with these drugs. There is clearly a need to identify
      new drugs that can benefit patients with chronic hepatitis B infections. Nucleic acid-based
      polymers (NAPs) are a new class of broad-spectrum antiviral compounds which act against HBV
      infection by blocking the release of the surface antigen protein (HBsAg) from infected
      hepatocytes.

      Current interim data analysis from the REP 102 assessing the activity of the NAP REP 9AC'
      (REP 2139, given as a calcium chelate complex [REP 2139-Ca]) in patients with chronic HBV
      infection indicates the following:

        1. REP 2139-Ca is generally well tolerated and patients tolerate short term combined
           treatment (13-26 weeks) of pegylated interferon and / or thymosin alpha

        2. REP 2139-Ca has achieved serum HBsAg reduction or clearance 9 of 9 patients receiving
           combined therapy.

        3. Appearance of substantial titers of serum anti-HBs occur with the addition of
           immunotherapy.

        4. After all treatment is withdrawn, 8 / 9 patients achieved HBV DNA &lt; 116 copies / ml
           (LLOQ of the Roche Cobas platform) and sustained suppression of viremia (HBV DNA &lt; 1000
           cpm, HBsAg &lt; 1 IU / ml) for a period of greater than 1 year was observed in four
           patients.

      This exploratory study is designed to examine if REP 2139-Ca can be safely combined with a
      full course of pegylated interferon in treatment naive patients and in patients with previous
      and continuing therapy with entecavir and that similar antiviral effects can be observed as
      in the previous REP 101 and 102 protocols.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Experiencing Treatment Emergent Laboratory Test Abnormalities or Adverse Events.</measure>
    <time_frame>48 weeks (treatment)</time_frame>
    <description>To record side effects, symptoms and adverse effects of exposure to REP 2139-Ca when combined pegylated interferon.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Experiencing Reductions in Serum HBsAg</measure>
    <time_frame>48 weeks (treatment)</time_frame>
    <description>To assess antiviral activity of REP 2139-Ca when combined with pegylated interferon on serum HBsAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Experiencing Reductions in Serum HBV DNA</measure>
    <time_frame>48 weeks (treatment)</time_frame>
    <description>To assess antiviral activity of REP 2139-Ca when combined with pegylated interferon on serum HBV DNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Experiencing Serum Anti-HBs &gt; 10 mIU / ml</measure>
    <time_frame>48 weeks (treatment)</time_frame>
    <description>To assess antiviral activity of REP 2139-Ca when combined with pegylated interferon on anti-HBsAg antibody titer.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients either treatment naive or with HBV DNA controlled with entecavir receive REP 2139-Ca in combination with pegylated interferon. Only patients receiving entecavir at enrollment continue to receive entecavir during treatment in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REP 2139-Ca</intervention_name>
    <description>the nucleic acid polymer REP 2139 formulated as a calcium chelate complex</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon</intervention_name>
    <description>immunotherapy</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>pegylated interferon alpha 2a, Pegasys(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>entecavir</intervention_name>
    <description>local generic entecavir</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>local generic entecavir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 55

          -  HBsAg+

          -  Anti-HBs negative

          -  Patients currently receiving nucleoside based HBV polymerase inhibitors may be
             included in the study at the discretion of the Principle Investigator.

          -  HIV / hepatitis C / hepatitis delta virus negative

          -  Fibrosis with compensation (as determined by Fibroscan and liver enzymes)

          -  Non cirrhotic

          -  No known active cytomegalovirus infection

          -  Willingness to utilize adequate contraception while being treated with REP 9AC' and
             for 6 months following the end of treatment

          -  Adequate venous access allowing weekly intravenous therapies and blood tests

        Exclusion Criteria:

          -  Evidence of cardiovascular disease

          -  Autoimmune hepatitis

          -  Presence of Wilson's disease

          -  Presence of severe NAFLD

          -  Evidence of any other co-existent liver disease

          -  Anti-nuclear antibody positive

          -  Ultrasonograph of hepato-biliary system: positive for cirrhosis of liver

          -  A history of ascites, hepatic encephalopathy or variceal hemorrhage

          -  Body weight &gt; 100 kg

          -  Platelet count &lt; 75,000, polymorphonuclear cell count &lt; 1,500 or hematocrit &lt; 33%

          -  alpha feto protein &gt; 100 ng/ml or the presence of a hepatic mass suggestive of
             hepatocellular carcinoma .

          -  Bilirubin &gt; 2.5 mg/dl

          -  Creatinine &gt; 1.5 mg/dl

          -  Platelet count &lt; 75,000 / cmm

          -  Serum albumin &lt; 35 mg/ml

          -  Poorly controlled diabetes mellitus

          -  Another serious medical disorder

          -  A serious psychiatric disorder

          -  Uncontrolled hypertension

          -  A history of alcohol abuse within the last year

          -  The use of illicit drugs within the past two years

          -  Inability to provide informed consent

          -  Positive pregnancy test

          -  Breastfeeding

          -  Inability or unwillingness to provide weekly blood samples

          -  Poor venous access making IV infusion too difficult
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mamun Al-Mahtab, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</affiliation>
  </overall_official>
  <reference>
    <citation>Noordeen F, Vaillant A, Jilbert AR. Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro. Antimicrob Agents Chemother. 2013 Nov;57(11):5291-8. doi: 10.1128/AAC.01003-13. Epub 2013 Aug 12.</citation>
    <PMID>23939902</PMID>
  </reference>
  <reference>
    <citation>Noordeen F, Vaillant A, Jilbert AR. Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother. 2013 Nov;57(11):5299-306. doi: 10.1128/AAC.01005-13. Epub 2013 Aug 12.</citation>
    <PMID>23939904</PMID>
  </reference>
  <reference>
    <citation>Noordeen F, Scougall CA, Grosse A, Qiao Q, Ajilian BB, Reaiche-Miller G, Finnie J, Werner M, Broering R, Schlaak JF, Vaillant A, Jilbert AR. Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection. PLoS One. 2015 Nov 11;10(11):e0140909. doi: 10.1371/journal.pone.0140909. eCollection 2015.</citation>
    <PMID>26560490</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>March 18, 2016</study_first_submitted>
  <study_first_submitted_qc>March 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2016</study_first_posted>
  <results_first_submitted>August 27, 2018</results_first_submitted>
  <results_first_submitted_qc>April 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 8, 2019</results_first_posted>
  <last_update_submitted>April 17, 2019</last_update_submitted>
  <last_update_submitted_qc>April 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nucleic acid polymer REP 2139 HBsAg hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>REP 2139</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental</title>
          <description>Patients to receive REP 2139-Ca in combination with pegylated interferon. Participants included in this study are either entecavir naive OR have prior exposure to entecavir.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental</title>
          <description>Participants receive REP 2139-Ca in combination with pegylated interferon. Participants included in this study are either entecavir naive OR have prior exposure to entecavir.
REP 2139-Ca: the nucleic acid polymer REP 2139 formulated as a calcium chelate complex
pegylated interferon: immunotherapy
Participants receiving entecavir at the start of therapy continue to receive entecavir during experimental therapy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bangladesh</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Experiencing Treatment Emergent Laboratory Test Abnormalities or Adverse Events.</title>
        <description>To record side effects, symptoms and adverse effects of exposure to REP 2139-Ca when combined pegylated interferon.</description>
        <time_frame>48 weeks (treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Participants receive REP 2139-Ca in combination with pegylated interferon. Participants included in this study are either entecavir naive OR have prior exposure to entecavir.
REP 2139-Ca: the nucleic acid polymer REP 2139 formulated as a calcium chelate complex
pegylated interferon: immunotherapy
Participants receiving entecavir at the start of experimental therapy continue to receive entecavir throughout experimental therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Experiencing Treatment Emergent Laboratory Test Abnormalities or Adverse Events.</title>
          <description>To record side effects, symptoms and adverse effects of exposure to REP 2139-Ca when combined pegylated interferon.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Experiencing Reductions in Serum HBsAg</title>
        <description>To assess antiviral activity of REP 2139-Ca when combined with pegylated interferon on serum HBsAg.</description>
        <time_frame>48 weeks (treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Participants receive REP 2139-Ca in combination with pegylated interferon. Participants included in this study are either entecavir naive OR have prior exposure to entecavir.
REP 2139-Ca: the nucleic acid polymer REP 2139 formulated as a calcium chelate complex
pegylated interferon: immunotherapy
Partiipants receiving entecavir at the start of experimental therapy continue to receive entecavir throughout experimental therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Experiencing Reductions in Serum HBsAg</title>
          <description>To assess antiviral activity of REP 2139-Ca when combined with pegylated interferon on serum HBsAg.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Experiencing Reductions in Serum HBV DNA</title>
        <description>To assess antiviral activity of REP 2139-Ca when combined with pegylated interferon on serum HBV DNA.</description>
        <time_frame>48 weeks (treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Participants receive REP 2139-Ca in combination with pegylated interferon. Participants included in this study are either entecavir naive OR have prior exposure to entecavir.
REP 2139-Ca: the nucleic acid polymer REP 2139 formulated as a calcium chelate complex
pegylated interferon: immunotherapy
Participants receiving entecavir at the start of experimental therapy continue to receive entecavir throughout experimental therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Experiencing Reductions in Serum HBV DNA</title>
          <description>To assess antiviral activity of REP 2139-Ca when combined with pegylated interferon on serum HBV DNA.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Experiencing Serum Anti-HBs &gt; 10 mIU / ml</title>
        <description>To assess antiviral activity of REP 2139-Ca when combined with pegylated interferon on anti-HBsAg antibody titer.</description>
        <time_frame>48 weeks (treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Participants receive REP 2139-Ca in combination with pegylated interferon. Participants included in this study are either entecavir naive OR have prior exposure to entecavir.
REP 2139-Ca: the nucleic acid polymer REP 2139 formulated as a calcium chelate complex
pegylated interferon: immunotherapy
Participants receiving entecavir at the start of experimental therapy continue to receive entecavir throughout experimental therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Experiencing Serum Anti-HBs &gt; 10 mIU / ml</title>
          <description>To assess antiviral activity of REP 2139-Ca when combined with pegylated interferon on anti-HBsAg antibody titer.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <desc>Weekly patient surveillance during therapy, every 1-8 weeks during follow-up</desc>
      <group_list>
        <group group_id="E1">
          <title>Experimental</title>
          <description>Participants receive REP 2139-Ca in combination with pegylated interferon. Participants included in this study are either entecavir naive OR have prior exposure to entecavir.
REP 2139-Ca: the nucleic acid polymer REP 2139 formulated as a calcium chelate complex
pegylated interferon: immunotherapy
Participants receiving entecavir at the start of experimental therapy continue to receive entecavir throughout experimental therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <description>Nephrotic syndrome occurred at week 38 exposure secondary to facial edema presence of urine albumin . PegasysÂ® therapy was halted early in this patient who recovered during the follow-up with supportive therapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Abdominal cramping</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dusgeusia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" events="23" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Reduced appetite</sub_title>
                <counts group_id="E1" events="21" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hairloss</sub_title>
                <counts group_id="E1" events="13" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Generalized body ache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ALT elevation</sub_title>
                <description>Transient, self resolving elevations in serum ALT not accompanied by elevation in bilirubin or INR.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>AST elevation</sub_title>
                <description>Transient, self resolving elevations in serum AST not accompanied by elevation in bilirubin or INR.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain / tingling in periphery</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Scientific Officer</name_or_title>
      <organization>Replicor Inc.</organization>
      <phone>514 733 1998</phone>
      <email>availlant@replicor.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

